Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa.

GlobeNewsWire • Dec 4, 2025

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa.

GlobeNewsWire • Dec 4, 2025

Royalty Pharma plc (RPRX) Presents at Evercore 8th Annual Healthcare Conference Transcript

Royalty Pharma plc (RPRX) Presents at Evercore 8th Annual Healthcare Conference Transcript

Seeking Alpha • Dec 3, 2025

Royalty Pharma plc (RPRX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Royalty Pharma plc (RPRX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seeking Alpha • Dec 2, 2025

Royalty Pharma to Present at Upcoming Investor Conferences

NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December:

GlobeNewsWire • Nov 26, 2025

Royalty Pharma: Guidance Raised Again, Platform Strength Intact -- Buy Reiterated

Royalty Pharma is reiterated as a Buy, supported by strong Q3 results, raised guidance, and disciplined capital deployment. The company trades at a notable discount to biopharma peers despite robust FCF, portfolio growth, and a diversified royalty-based business model. Platform model delivering diversified biopharma exposure, buybacks ongoing, and new deals to be priced in. Our buy is then confirmed.

Seeking Alpha • Nov 15, 2025

Royalty Pharma plc (RPRX) Q3 2025 Earnings Call Transcript

Royalty Pharma plc ( RPRX ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants George Grofik - Senior VP and Head of Investor Relations & Communications Pablo Legorreta - Founder, Chairman of the Board & CEO Marshall Urist - Executive Vice President of Research & Investments Christopher Hite - Vice Chairman & Executive VP Terrance Coyne - Executive VP & CFO Conference Call Participants Asad Haider - Goldman Sachs Group, Inc., Research Division Hardik Parikh - JPMorgan Chase & Co, Research Division Geoffrey Meacham - Citigroup Inc., Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Division Terence Flynn - Morgan Stanley, Research Division Michael Nedelcovych - TD Cowen, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. Welcome to Royalty Pharma Third Quarter Earnings Conference Call.

Seeking Alpha • Nov 5, 2025

Royalty Pharma Reports Third Quarter 2025 Results

Portfolio Receipts growth of 11% to $814 million; Royalty Receipts growth of 11% Net cash provided by operating activities of $703 million Raised full year 2025 guidance: Portfolio Receipts expected to be $3,200 to $3,250 million NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts. “We delivered strong third quarter 2025 results, raised our full year guidance and are on track to deliver another year of double-digit top-line growth,” said Pablo Legorreta, Royalty Pharma's founder and Chief Executive Officer.

GlobeNewsWire • Nov 5, 2025

Royalty Pharma (RPRX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Royalty Pharma (RPRX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • Nov 5, 2025

Royalty Pharma (RPRX) Beats Q3 Earnings and Revenue Estimates

Royalty Pharma (RPRX) came out with quarterly earnings of $1.17 per share, beating the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $1.04 per share a year ago.

Zacks Investment Research • Nov 5, 2025